Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Anaptysbio (ANAB) over the last 11 years, with Q3 2025 value amounting to $33.2 million.

  • Anaptysbio's Accumulated Expenses fell 1361.94% to $33.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.2 million, marking a year-over-year decrease of 1361.94%. This contributed to the annual value of $39.5 million for FY2024, which is 2755.84% up from last year.
  • Per Anaptysbio's latest filing, its Accumulated Expenses stood at $33.2 million for Q3 2025, which was down 1361.94% from $30.2 million recorded in Q2 2025.
  • In the past 5 years, Anaptysbio's Accumulated Expenses registered a high of $39.5 million during Q4 2024, and its lowest value of $11.8 million during Q1 2021.
  • In the last 5 years, Anaptysbio's Accumulated Expenses had a median value of $30.2 million in 2025 and averaged $25.8 million.
  • Per our database at Business Quant, Anaptysbio's Accumulated Expenses crashed by 2240.48% in 2021 and then surged by 11038.65% in 2023.
  • Quarter analysis of 5 years shows Anaptysbio's Accumulated Expenses stood at $12.9 million in 2021, then skyrocketed by 68.31% to $21.6 million in 2022, then skyrocketed by 43.15% to $31.0 million in 2023, then increased by 27.56% to $39.5 million in 2024, then decreased by 16.02% to $33.2 million in 2025.
  • Its last three reported values are $33.2 million in Q3 2025, $30.2 million for Q2 2025, and $36.0 million during Q1 2025.